Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
MDGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$189.00 - $377.46
Previous CloseN/A
Volume47.78K
Average Volume (3M)389.85K
Market Cap
$7.37B
Enterprise Value$5.96B
Total Cash (Recent Filing)$100.02M
Total Debt (Recent Filing)$119.57M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
May 13, 2025EPS Estimate
-3.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.11
Shares Outstanding22,080,246
10 Day Avg. Volume300,143
30 Day Avg. Volume389,853
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)41.87
Price to Cash Flow (P/CF)-18.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit34.24
Enterprise Value/Ebitda-13.23
Forecast
1Y Price Target
$413.87Price Target Upside22.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRezdiffra revenues for the fourth quarter and fiscal year 2024 came in at the top of the preannounced range, showing significant growth and exceeding previous estimates.
Market AccessMDGL's ongoing launch progress is impressive with more than 80% of commercial insurance plan lives covered, ensuring broad access to their new drug.
Market DemandRezdiffra's launch is gaining momentum, with strong patient demand and favorable physician prescribing trends.
Bears Say
Investor FocusInvestor focus remains on the commercial launch for Rezdiffra and its progress with payor and market building activities, as well as prescriber and patient uptake.
Market CompetitionRezdiffra shows promising therapeutic benefits in NASH patients, which strengthens its market position amidst emerging competition.
Regulatory ExpectationsMDGL confirmed that an EMA decision is expected with plans to commence a country-by-country launch beginning with Germany pending EMA approval.
---
Ownership Overview
19.56% Insiders
27.43% Mutual Funds
0.07% Other Institutional Investors
38.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MDGL FAQ
What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Madrigal Pharmaceuticals Inc lowest stock price was $189.00 and its highest was $377.46 in the past 12 months.
What is Madrigal Pharmaceuticals Inc’s market cap?
Madrigal Pharmaceuticals Inc’s market cap is $7.37B.
When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
Madrigal Pharmaceuticals Inc’s upcoming earnings report date is May 13, 2025 which is in 46 days.
How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
Madrigal Pharmaceuticals Inc released its earnings results on Feb 26, 2025. The company reported -$2.71 earnings per share for the quarter, beating the consensus estimate of -$3.92 by $1.21.
Is Madrigal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued.
Does Madrigal Pharmaceuticals Inc pay dividends?
Madrigal Pharmaceuticals Inc does not currently pay dividends.
What is Madrigal Pharmaceuticals Inc’s EPS estimate?
Madrigal Pharmaceuticals Inc’s EPS estimate is -3.74.
How many shares outstanding does Madrigal Pharmaceuticals Inc have?
Madrigal Pharmaceuticals Inc has 22,080,246 shares outstanding.
What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
Madrigal Pharmaceuticals Inc reported an EPS of -$2.71 in its last earnings report, beating expectations of -$3.92. Following the earnings report the stock price went up 14.989%.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MDGL
---
Madrigal Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$413.87 (22.71% Upside)
$413.87 (22.71% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 160.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $24.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 10.0%
Last 30 Days ▲ 10.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.81%
12-Months-Change
Fundamentals
Return on Equity
-80.35%
Trailing 12-Months
Asset Growth
62.71%
Trailing 12-Months
Company Description
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc. (MDGL) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead product candidate, resmetirom, is being evaluated for its potential to treat non-alcoholic steatohepatitis (NASH), a progressive liver disease. Madrigal Pharmaceuticals operates predominantly in the biotechnology and pharmaceuticals sector, leveraging cutting-edge research and development to address significant unmet medical needs.
---
MDGL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Madrigal Pharmaceuticals demonstrated strong performance with the successful launch of Rezdiffra, significant prescriber engagement, and promising clinical data. Despite rising expenses and market challenges, the company's financial health and strategic positioning remain robust.Read More>---
MDGL Stock 12 Month Forecast
Average Price Target
$413.87
▲(22.71% Upside)
Technical Analysis
Altimmune
―
Galectin Therapeutics
―
Galmed Pharmaceuticals
―
Viking Therapeutics
―
Akero Therapeutics
―
Best Analysts Covering MDGL
1 Year
1 Year Success Rate
16/20 ratings generated profit
1 Year Average Return
+34.26%
reiterated a buy rating 23 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +34.26% per trade.
---